Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure disorders.
## Primary Indications
* Adjunctive therapy for seizures in patients with Lennox-Gastaut syndrome (LGS).
* Adjunctive therapy for other types of seizures, including focal onset seizures.
## Adult Dosing
* **LGS:** Initial dose is typically 5 mg twice daily. Can be increased by 5-10 mg every week. Maintenance dose is usually 10-20 mg twice daily, with a maximum of 20 mg twice daily.
* **Other Seizures:** Initial dose is typically 5 mg twice daily. Can be increased by 5-10 mg every week. Maintenance dose is usually 10-20 mg twice daily, with a maximum of 20 mg twice daily.
## Pediatric Dosing
* **LGS (2 years and older):** Initial dose is typically 5 mg twice daily. Can be increased by 5-10 mg every week. Maintenance dose is usually 10-20 mg twice daily, with a maximum of 20 mg twice daily.
* **Other Seizures (2 years and older):** Initial dose is typically 5 mg twice daily. Can be increased by 5-10 mg every week. Maintenance dose is usually 10-20 mg twice daily, with a maximum of 20 mg twice daily.
* Dosing for children under 2 years of age has not been established and should be approached with extreme caution and expert consultation.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are routinely recommended, but initiation at lower doses and slow titration is advisable.
* **Renal Impairment:** Use with caution. No specific dosage adjustments are routinely recommended, but initiation at lower doses and slow titration is advisable.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, and fatigue. Serious adverse effects include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, and withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Potentiate CNS depressant effects, increasing risk of respiratory depression, sedation, and coma.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase clobazam levels. Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease clobazam levels.
* **Antiepileptic Drugs (AEDs):** May affect the efficacy of other AEDs.
## Monitoring
* Monitor for efficacy in seizure control.
* Monitor for signs and symptoms of adverse effects, especially somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal if dose is reduced or discontinued.
* Consider therapeutic drug monitoring for clobazam and its active metabolite, N-desmethylclobazam, particularly in patients with fluctuating clinical response or suspected non-adherence.
## Clinical Pearls
* Clobazam should be tapered slowly when discontinuing to avoid withdrawal symptoms.
* Be aware of the risk of paradoxical reactions, such as increased seizure frequency or severity.
* Due to the risk of severe skin reactions, patients should be educated to discontinue the drug and seek immediate medical attention if a rash develops.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and local protocols for definitive patient management.
